Study S001346

A Study to Evaluate the Safety, Tolerability, and Absolute Bioavailability of Subcutaneous LY2189265

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01301092
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 30
Start: 2011-02
Primary completion: 2011-08
Lead sponsor: Eli Lilly and Company
Conditions: Diabetes Mellitus, Type II
Interventions: BIOLOGICAL:LY2189265
Results posted: TRUE
Secondary identifiers: OTHER:H9X-MC-GBDR

Registered primary outcomes

Dose Normalized Area Under the Concentration Time Curve (AUC) of LY2189265: Subcutaneous (SC) to Intravenous (IV) [Predose up to 336 hours postdose]
Maximum Concentration (Cmax) of LY2189265: Subcutaneous (SC) to Intravenous (IV) [Predose up to 336 hours postdose]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.